Compare Gilead Sciences, Inc. (GILD) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Banco Santander SA — how do they compare? Gilead Sciences, Inc. trades at $132.98 (market cap $163.51B), while Banco Santander SA trades at $13.66 (market cap $195.14B). The key difference: Banco Santander SA is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SAN | |
|---|---|---|
Market Cap | $163.51B | $195.14B |
Sector | Health | Financials |
52-Week High | $155.80 | $14.37 |
52-Week Low | $108.22 | $8.40 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Banco Santander (SAN) trades at $13.63, showing modest daily movement with a neutral technical outlook. The bank maintains solid profitability with a 26.72% net income margin and 16.18% ROE, though recent earnings have been mixed with two misses and one beat in the last four quarters. Recent strategic moves include the $12.2 billion Webster Bank acquisition (OCC approved June 2026) and TSB integration, positioning for growth in key markets. Cash flow trends show challenges with negative operating cash flow in 2024-2025, while analyst consensus remains bullish with 64% buy ratings.
SAN presents a value opportunity with reasonable valuation (P/E 13.73, P/B 1.64) and 64% analyst buy consensus, supported by strategic acquisitions and AI-driven efficiency targets. Key risks include negative cash flow trends, regulatory scrutiny in Spain's mortgage market (Reuters June 2026), and integration challenges from recent acquisitions. The bank's focus on operational transformation and capital return targets (doubling cash DPS by 2028) provides potential upside if execution improves cash generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
